Top Medical Billing Companies for Infectious Disease Practices in Delaware

Bicillin is a medication, so billing typically involves identifying the appropriate drug J-code or other applicable drug code, the administered units, and a separate administration code when supported. The correct coding depends on the specific Bicillin product, dose, route, documentation, payer policy, and whether the service is covered under the medical benefit. Practices should verify current coding and payer requirements before submitting a claim.

CPT code 96372 represents a therapeutic, prophylactic, or diagnostic injection administered subcutaneously or intramuscularly. Documentation should support the medication, dose, route, medical necessity, and administering professional. Whether the code is payable separately can depend on the accompanying drug code, visit services, payer policy, bundling edits, and the patient’s benefit structure. Accurate charge capture and payer-specific review are important for infectious disease practices.

Support may include charge entry, coding review, claim scrubbing, submission, rejection clearing, denial management, payment reconciliation, aging A/R follow-up, credentialing, payer enrollment, eligibility verification, prior authorization, and revenue-cycle consulting. Infectious disease practices may also need help coordinating E/M, infusion, drug, OPAT, and hospital-related billing workflows so documentation and reimbursement processes remain aligned.

Infusion and drug claims require attention to product identification, units, administration services, documentation, authorization, and whether coverage falls under the medical or pharmacy benefit. A billing review can connect clinical records and charge capture with payer requirements, then identify rejected, denied, or underpaid claims. Practices should also review acquisition and reimbursement assumptions using their own contracts and current payer information.

Common causes include missing authorization, medical-versus-pharmacy benefit confusion, incomplete consult documentation, drug or administration coding issues, unit or NDC mismatches, and payer-specific claim requirements. Effective denial management groups claims by root cause, supports appeals with clinical documentation, and shares findings with clinical, coding, and front-office teams so recurring process problems can be addressed.

Yes. Eligibility and authorization support can review benefits, determine whether an OPAT course is processed under the medical or pharmacy benefit, and track prior authorization requests for therapy and specialty drugs. The workflow should connect authorization status with clinical documentation, planned services, and claim submission requirements. This helps practices identify coverage concerns before they become unreimbursed drug or infusion costs.

Payment reconciliation compares payer payments with expected reimbursement for drug, administration, and E/M claims. The review can identify short-pays, incorrect fee schedule application, unit problems, NDC mismatches, and other discrepancies. Findings may then be disputed and tracked through recovery. Contract terms, payer policies, claim details, and the practice’s own reimbursement data determine the appropriate review approach.

A practical review follows the workflow from referral to first dose to final payment. It examines documentation, coding, eligibility, authorization, drug acquisition, infusion billing, denials, underpayments, A/R follow-up, and payer or hospital coverage agreements. The goal is to trace delayed or missing revenue to its source and prioritize workflow changes using the practice’s own operational and financial information.